HDAC9 and mature T-cell and NK-cell non-Hodgkin lymphoma: In addition, three other HDAC inhibitors have been approved by the FDA, romidepsin, belinostat and panobinostat, which have primarily been used in multiple myeloma, peripheral T‐cell lymphoma (PTCL) and cutaneous T‐cell lymphoma.117